ProUroCare Medical(OTC) PUMD

ProUroCare Medical Inc. is focused on developing innovative products for the precise identification and assessment of male prostate diseases. The company's flagship offering, the ProUroScan System, enhances the ability of physicians to document prostate irregularities discovered during examinations.

Products and Services

• ProUroScan System for prostate imaging
• Licensing agreements with Artann Laboratories Inc.
• Ongoing development and commercialization of medical devices

Growth Outlook

• Strategic partnerships aim to enhance market reach
• Focus on expanding product offerings in the healthcare sector
• Potential for increased demand in prostate health diagnostics

Financial Highlights

• Recent quarterly net income of -$407,827
• Trailing twelve months (TTM) revenue of $0
• Current ratio at 0.055, indicating liquidity challenges

ProUroCare Medical Inc. operates in the medical devices industry, specifically targeting prostate health diagnostics. The ProUroScan System represents a significant advancement in imaging technology, which could lead to improved patient outcomes. The company has established strategic agreements to facilitate the ongoing development and commercialization of its products, positioning itself for future growth. Despite recent financial challenges, including a net income loss and a current ratio indicating liquidity issues, the company is focused on expanding its market presence. The potential for increased demand in prostate health diagnostics presents an opportunity for future revenue growth. Investors may find interest in the company's innovative approach and strategic partnerships as it navigates the evolving healthcare landscape.